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Background: Angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) are regula-
tors of endothelial permeability.
Objective: Plasma concentrations of Ang-2 and VEGF are increased in dogs with systemic inflamma-
tory response syndrome (SIRS) and sepsis and are correlated with disease severity and outcome.
Animals: Healthy dogs (n = 18) and client-owned dogs with SIRS (n = 34) or sepsis (n = 25).
Methods: Prospective observational study. Ang-2 and VEGF concentrations in admission plasma
samples were compared between healthy dogs and dogs with SIRS or sepsis, and between survi-
vors and non-survivors. Correlations with the acute patient physiologic and laboratory evalua-
tion (APPLEfast) disease severity score were examined.
Results: Median Ang-2 was significantly higher in dogs with SIRS (19.3; interquartile range [IQR]:
8.6-25.7 ng/mL) and sepsis (21.2; IQR: 10.3-30.1 ng/mL) compared to healthy dogs (7.6; IQR:
6.7-9.8 ng/mL). Ang-2 was significantly higher in non-survivors (24.1; IQR: 11.9-50.0 ng/mL) than
survivors (10.2; IQR: 7.2-21.5 ng/mL) but did not correlate with the APPLEfast score. Admission
Ang-2 predicted negative outcome in dogs with SIRS and sepsis with reasonable accuracy (area
under the curve [AUC]: 0.75, confidence interval [CI]: 0.59-0.85; sensitivity: 0.5, CI: 0.29-0.71;
specificity: 0.87, CI: 0.75-0.95); differentiation between sepsis and SIRS was poor (AUC: 0.58).
Plasma VEGF was significantly higher in dogs with sepsis (45; IQR: 14-107.5 pg/mL) than in dogs
with SIRS (3.3; IQR: 0-35.6 pg/mL) or healthy dogs (0; IQR: 0 pg/mL; P = 0.008). VEGF was signif-
icantly (P = .0004) higher in non-survivors (34.5; IQR: 0-105.7 pg/mL) than in survivors (0; IQR:
0-55.2 pg/mL). The ability of VEGF to predict a negative outcome was poor.
Conclusions and Clinical Importance: Ang-2 may represent a useful additional prognostic
marker in dogs with SIRS.
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1 | INTRODUCTION
Systemic inflammatory response syndrome (SIRS) and sepsis are com-
mon in both humans and animals.1,2 Systemic inflammation, endothe-
lial activation and dysfunction causing increased vascular permeability,
loss of vascular tone, and impaired coagulation are hallmarks of the
pathophysiology of SIRS and sepsis.3,4 If uncontrolled, SIRS and sepsis
ABBREVIATIONS: AHDS, acute hemorrhagic diarrhea syndrome; ALT, alanine
aminotransferase; Ang-2, angiopoietin-2; APPLE, acute patient physiologic and
laboratory evaluation; AUC, area under the curve; CI, confidence interval; CRP, C-
reactive protein; CV%, coefficient of variation; GDV, gastric dilatation volvulus;
IQR, interquartile range; LLD, lower limit of detection; PBMCs, peripheral blood
mononuclear cells; PCR, polymerase chain reaction; ROC, receiver-operating char-
acteristics; SIRS, systemic inflammatory response syndrome; VEGF, vascular endo-
thelial growth factor; WBC, white blood cell.
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may lead to distributive shock, multi-organ dysfunction, and death.
Early recognition and aggressive intervention are therefore crucial.5
Angiopoietin (Ang)-2 and vascular endothelial growth factor
(VEGF) are major players in the regulation of vascular endothelial
activation and dysfunction.6–8 Ang-2 is predominantly synthesized by
endothelial cells, stored in cytoplasmic Weibel-Palade bodies and
released into the bloodstream upon endothelial activation.7,9 The
balance between the agonistic ligand Ang-1 and the antagonistic
Ang-2 regulates baseline endothelial barrier function and its response
to injury. Although Ang-1 promotes vessel stability, inhibits inflamma-
tion, and limits permeability,10–14 Ang-2 promotes apoptosis, inflam-
mation, adhesion, and vascular dysfunction.11,15–17
Vascular endothelial growth factor is a key regulator of vasculogen-
esis and angiogenesis, promoting endothelial cell survival, growth, and
migration.18 It is produced by synovial cells, macrophages, leukocytes,
platelets, and endothelial cells.19 During inflammation, VEGF promotes
vasodilatation and permeability thus playing a crucial role in disruption
of the endothelial barrier function. Vascular endothelial growth factor
and Ang-2 are interrelated in that Ang-2 is required for the induction of
vascular leakage in response to pro-inflammatory cytokines and VEGF.20
A strong association between increased serum concentrations of
Ang-2 with increasing clinical severity and mortality has been demon-
strated in numerous studies in human medicine including patients
with sepsis,10,16,21–30 multiple trauma,31,32 neoplasia,33,34 chronic kid-
ney disease,12 and ventilator-associated pneumonia.28
Although most authors agree that plasma VEGF concentration is
increased in systemic inflammation in humans, studies evaluating
whether VEGF correlates with disease severity and outcome have
yielded conflicting results.35–37
Besides the potential roles of Ang-2 and VEGF as diagnostic and
prognostic markers, they are interesting tools to better understand
the pathophysiology of vascular leakage syndromes. Furthermore, the
availability of pharmacologic agents to block VEGF, Ang-2, or both
may provide novel therapeutic strategies for conditions leading to
endothelial dysfunction, such as SIRS and sepsis.8,24
The purpose of our study was to compare Ang-2 and VEGF concen-
trations in dogs with SIRS and sepsis and to examine correlations
between Ang-2 and VEGF concentrations with disease severity and out-
come. We hypothesized that plasma concentrations of Ang-2 and VEGF
would be significantly higher in dogs with SIRS or sepsis compared to
healthy dogs and that non-survivors would have significantly higher
plasma concentration of Ang-2 and VEGF compared to survivors. Further-
more, we hypothesized that there would be a significant correlation
between Ang-2 and VEGF and other knownmarkers that have been stud-
ied in the context of systemic inflammation including C-reactive protein
(CRP), lactate, albumin, bilirubin, and Acute Patient Physiologic and Labo-
ratory Evaluation (APPLEfast) score, a 5-variable disease severity model
based on glucose, albumin, mentation score, platelet count, and lactate.
2 | MATERIALS AND METHODS
2.1 | Study design
Healthy dogs and dogs meeting SIRS criteria (see below) admitted to
the intensive care unit of a university referral hospital between March
2015 and April 2016 were included in this prospective observational
study. The study protocol was approved by the local ethics commit-
tee. Owner consent for the collection of blood samples from healthy
dogs and the use of clinical data and surplus samples from dogs with
SIRS or sepsis was obtained.
2.2 | Animals
Dogs were deemed healthy based on an uneventful medical history,
normal physical examination, and unremarkable CBC and plasma
biochemistry, including normal CRP. A diagnosis of SIRS was based on
published clinical criteria for SIRS in dogs.38 Briefly, dogs were consid-
ered to have SIRS if they fulfilled ≥ 2 of the following criteria at
admission: body temperature < 38.1C or > 39.2C; heart rate > 120/
min; respiratory rate > 20/min; white blood cell (WBC) count < 6.0 ×
109/L (6 000/μL) or > 16.0 × 109/L (16 000/μL), and percentage of
bands > 3% of the total WBC count. Sepsis was diagnosed in dogs
meeting SIRS criteria, if a viral, bacterial, or protozoal infection could
be identified by serology. Polymerase chain reaction (PCR), cytology,
histopathology, bacterial culture, intraoperative evidence of a septic
focus or if an infectious cause was strongly suspected and clear
improvement with antibiotic treatment occurred.
The severity of illness was assessed at presentation using the
APPLEfast score. This model is based on 5 variables—glucose, albumin,
mentation score, platelet count, and lactate—and has been shown to
predict the probability of death in critically ill dogs independent of
their diagnosis.39 The mentation score was assessed at admission
before any analgesics or sedatives had been given. The APPLEfast
score ranges from 0 to 50, and the algorithm for calculation of the
score is shown in Supporting Information Supplemental Table 1. In
the original validation cohort, the APPLEfast score showed a specificity
of 85% to predict a negative outcome when a score > 25 was used as
a cutoff value.39
2.3 | Sample collection and handling
Blood was collected at admission from the cephalic, saphenous, or
jugular vein into tubes containing ethylenediaminetetraacetic acid or
lithium-heparin (Microvette 200 μL, Lithium-Heparin, orange; Sarstedt
AG, Nümbrecht, Germany). Heparinized blood was centrifuged at
4 000 rpm for 10 minutes at 4C to separate plasma from cellular
components. Plasma then was used for biochemistry, and the
remaining sample aliquoted and frozen at −80C.
2.4 | Clinical evaluation
All dogs underwent standard diagnostic evaluation including clinical
examination, CBC, and plasma biochemistry including CRP (Canine
CRP assay; Randox Reagents, London, United Kingdom). Concentra-
tions of electrolytes, ionized calcium, and lactate were measured on
whole blood immediately after blood collection (RapidPoint 500
System; Siemens Healthineers, Erlangen, Germany). Urinalysis, micro-
biologic analysis, serologic testing, diagnostic imaging, surgery, or
some combinations of these was performed as required based on the
individual patient and at the discretion of the treating veterinarian.
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2.5 | Measurements of Ang-2
Plasma Ang-2 concentration was measured according to the manufac-
turer's instructions using a commercial ELISA test kit (Human
Angiopoietin-2 Immunoassay; R&D Systems, Minneapolis, Minnesota.
Product datasheet available at: https://www.rnsystems.com/products/
human-angiopoietin-2-quantikine-elisa-kit_dang20, accessed March
5, 2017) for use in humans that was validated for the use in dogs.40
Tests were run in duplicate and by the same person. If the coefficient
of variation (CV%) between duplicates was > 10%, measurements were
repeated. Plasma samples initially were diluted 1:5 with Calibrator
Diluent (Human Angiopoietin-2 Immunoassay; R&D Systems. Product
datasheet available at: https://www.rnsystems.com/products/human-
angiopoietin-2-quantikine-elisa-kit_dang20, accessed March 5, 2017). If
the measured Ang-2 concentration was outside the range of the stan-
dard curve (21-3 000 pg/mL), samples were further diluted (up to
50 times) and measurements were repeated. Assay lower limit of detec-
tion (LLD) was 21.3 pg/mL. Intra-assay and inter-assay variability were
assessed in a previous study and were 4% and 6.7%, respectively.41
2.6 | Measurement of VEGF
Plasma VEGF concentration was measured using a validated commer-
cial VEGF ELISA kit (https://www.rndsystems.com/products/canine-
vegf-quantikine-elisa-kit_cave00) for dogs. Plasma samples were diluted
in 1:2 ratio with 1% bovine serum albumin in phosphate-buffered
saline. Because no result was outside the upper range of the standard
curve, further dilution was not necessary. If the CV% between dupli-
cates was > 10%, measurements were repeated. Because plasma was
first used to perform biochemistry and additional testing followed by
Ang-2, VEGF could only be measured in 54 of 77 dogs because of
insufficient sample volume in the remaining 23 dogs.
As part of our own pre-analytical validation, canine peripheral
blood mononuclear cells (PBMCs) were isolated from heparinized
blood of a healthy dog by Biocoll density gradient centrifugation
(Biocoll density 1.077; Biochrom, www.biochrom.de). The PBMCs
were seeded at 2 × 106/mL in Roswell Park Memorial Institute Gluta-
max 1640 medium supplemented with 10% inactivated fetal calf
serum (Gibco; www.thermofisher.com), 100 IU/mL penicillin, and
100 μg/mL streptomycin (SO613, Biochrom) and cultured for 6 days
with 5 μg/mL Concanavalin A (Sigma-Aldrich; www.sigmaaldrich.com).
The supernatant was harvested and stored at −80C in aliquots until
analysis. This supernatant then was used as a positive control and to
estimate inter-assay variability, which was 4.6%. Intra-assay variability
was assessed on 15 aliquots measured in parallel on the same plate
and was 4.9%. Serum VEGF was stable during 3 freeze-thaw cycles
(Supporting Information Supplemental Table 2). The LLD of the assay
was 15 pg/mL. Values below the LLD were set at 15 pg/mL for
analysis.
2.7 | Statistical analysis
Data were evaluated using a commercial statistical software package
(NCSS11 Statistical Software, 2016; NCSS; LLC, Kaysville, Utah, avail-
able at: ncss.com/software/ncss). Patient characteristics including sex,
neuter status, age, and body weight were compared between healthy
dogs and dogs with SIRS or sepsis. Shapiro Wilk testing indicated non-
normal distribution for several continuous variables, which therefore
were reported as median and interquartile range (IQR).
Differences in plasma Ang-2 and VEGF concentrations between
dogs with SIRS or sepsis and healthy dogs and survivors and non-
survivors were assessed using the Kruskal-Wallis multiple-comparison
Z-value test. The Kruskal-Wallis multiple-comparison Z-value test also
was used to assess the differences in multiple variables including
APPLEfast score, neutrophil count, band neutrophils, urea, creatinine, lac-
tate, albumin, bilirubin, and CRP between survivors and non-survivors.
The VEGF concentrations of healthy dogs and dogs with SIRS and
sepsis and survivors and non-survivors were compared using Fisher's
exact test. To correct for multiple comparisons, Bonferroni correction
was used. Results below the LLD were set at 15 pg/mL for analysis.
In general, data points were classified as outliers if they were
more than 1.5 times the IQR above the third quartile or below the first
quartile. Dogs euthanized for financial reasons rather than intractable
disease were excluded from the outcome analysis.
Because the non-normal distribution of the data, the correlation
of Ang-2 and VEGF, and the associations of Ang-2 and VEGF with
clinical and laboratory variables and the APPLEfast score were
assessed using the Spearman rank correlation test.
Statistical significance was set at P < 0.05.
The performance of Ang-2 and VEGF to predict a negative out-
come was assessed using receiver-operating characteristics (ROC)
analysis. For comparison, ROC analysis also was performed for CRP,
lactate, albumin, and APPLEfast score.
Optimal cut-off points for sensitivity and specificity were deter-
mined using the most favorable cost-benefit ratios to obtain the larg-
est possible proportion of correctly classified dogs while ensuring that
sensitivity and specificity were > 0.3.
3 | RESULTS
3.1 | Study population
Seventy-seven dogs were enrolled in the study: 34 dogs were diag-
nosed with SIRS, 25 with sepsis, and 18 dogs were healthy. No signifi-
cant differences were found between groups regarding age, neuter
status, and body weight (Table 1). Ten dogs were crossbreds and
67 were purebreds belonging to 37 different breeds, with the most
common breeds being Bernese Mountain dog (n = 7), Siberian Husky
(n = 7), Labrador Retriever (n = 5), Malinois (n = 4), Border Collie
(n = 3), German Shepherd (n = 3), and Cocker Spaniel (n = 3).
The most common sources of sepsis were septic peritonitis (n = 8),
followed by pyometra (n = 4), pyelonephritis (n = 4), pneumonia
(n = 2), and 1 of each of the following: pyothorax, prostatic abscess,
babesiosis, ehrlichiosis, parvovirus infection, cholangitis, and bacterial
cystitis with urosepsis. Babesiosis was diagnosed based on a positive
Babesia PCR result. The dog with ehrlichiosis had an increased antibody
titer using 2 different antibody tests (SNAP 4Dx Plus Test; Idexx, West-
brook, Maine, and IFA). Bacterial cholangitis was diagnosed based on
the presence of neutrophilic inflammation and bacteria on histopatho-
logic examination of the gall bladder wall after cholecystectomy.
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Dogs with SIRS were diagnosed with hemangiosarcoma (n = 8);
renal disease including amyloidosis (n = 1), glomerulonephritis (n = 1),
ethylene glycol intoxication (n = 1), and acute kidney injury of
unknown origin (n = 1); pancreatitis (n = 3); steroid-responsive
meningitis-arteritis (n = 2); aspiration pneumonia (n = 2); acute hem-
orrhagic diarrhea syndrome (AHDS) (n = 2); foreign body ileus (n = 2);
gastric dilatation volvulus (GDV) (n = 2); and, 1 of each ulcerative gas-
tritis, chronic active hepatitis, immune-mediated hemolytic anemia,
Evan's syndrome, immune-mediated polyarthritis, myositis, vasculitis,
pulmonary eosinophilic granuloma, and snake bite. In the 2 dogs with
aspiration pneumonia, the diagnosis was based on consistent histori-
cal, clinical, and radiographic findings. These 2 dogs were classified in
the SIRS group instead of the sepsis group because aspiration pneu-
monia is not primarily a consequence of bacterial infection, but an
inflammatory response to the aspirated material.
Population characteristics, APPLEfast score, and outcome for dogs
with SIRS and sepsis are shown in Table 1. As expected, SIRS and sep-
sis animals significantly differed from healthy dogs in plasma concen-
trations of albumin, bilirubin, and CRP. Dogs with sepsis had a
significantly lower total neutrophil count, with a higher number of
band neutrophils compared to dogs with SIRS. No significant differ-
ences were found in APPLEfast score and duration of hospitalization
or outcome between the SIRS and sepsis groups.
Differences in baseline blood variables between survivors and
non-survivors are shown in Table 2. Median APPLEfast score, band
neutrophils, and concentrations of urea, creatinine, lactate, bilirubin,
and CRP were significantly higher and albumin were significantly
lower in non-survivors compared to survivors.
3.2 | Ang-2, VEGF, CRP, and lactate concentrations
Median Ang-2 concentration was significantly higher in dogs with
SIRS and sepsis compared to healthy dogs (Figure 1A). Non-survivors
had significantly higher plasma Ang-2 concentrations compared to
dogs that survived to discharge (Figure 1B).
Plasma concentrations of VEGF were below the level of detection
in all 7 healthy dogs tested, in 20 of 29 dogs with SIRS, and in 6 of
18 dogs with sepsis. Median plasma concentrations of VEGF were
higher in dogs with sepsis compared to dogs with SIRS and healthy dogs
(Figure 2A) and in non-survivors compared to survivors (Figure 2B).
After Bonferroni correction, differences were nonsignificant.
Median CRP and lactate concentrations are shown in Table 1.
Median CRP concentration was significantly higher in dogs with SIRS
and sepsis compared to healthy dogs (Table 1) and significantly higher
in non-survivors compared to survivors (Table 2). No significant differ-
ence in CRP was found between dogs with SIRS and those with sepsis.
Non-survivors had significantly higher lactate concentrations (3.5;
IQR: 2.3-5.3 mmol/L) compared to survivors (1.0; IQR: 1.5-2.8 mmol/L).
TABLE 1 Patient characteristics of healthy dogs and dogs with SIRS or sepsis
Variable
Healthy SIRS Sepsis
n Median (IQR) n Median (IQR) n Median (IQR)
Age (y) 18 6.9 (4.9-9.0) 34 8.7 (6.3-10.4) 25 7.5 (5-9.5)
Body weight (kg) 18 25.8 (22.8-29.9) 34 27.4 (16.3-36.7) 25 23.5 (12.7-26.9)
Sex 18 34 25
Male (n, intact/neutered) 9 (5/4) 18 (11/7) 21 (10/11)
Female (n, intact/neutered) 9 (6/3) 16 (9/7) 14 (2/12)
APPLEfast score NA 34 25.3 (24-27.4) 25 26.3 (24.9-27.5)
Neutrophil count (109/L) 18 4.9 (4.1-5.4) 34 16.2 (11.1-22.9) 25 11.5 (7–14)
Band neutrophils (%) 18 0.1 (0-0.3) 34 5 (2.7-9.3) 25 15.4 (7-28.6)#
Albumin (g/L) 18 34.5 (32.5-35.7) 34 24.5 (21.2-29.5) 25 24.5 (21-29.8)
Bilirubin (μmol/L) 18 1.4 (1-1.7) 34 3.2 (2.1-5.4)** 25 5 (2.3-25.9)**
CRP (mg/L) 18 2.7 (0.7-5.9)* 34 106.2 (68.1-143.3)** 25 123 (71.4-1624)**
Lactate (mmol/L) NA 34 2.5 (2-3.8) 25 2.6 (2.1-3.2)
Duration of hospital stay (d) 30 3 (1-6.5) 24 3 (2.6.8)
Outcome
Alive to discharge, n (%) NA 23 23 (68) 12 12 (48)
Euthanized/died, n (%) NA 11 7/4 (32) 13 9/4 (52)
Abbreviations: APPLEfast score, Five-parameter acute physiologic and laboratory evaluation score (0-50); CRP: C-reactive protein; IQR, interquartile range;
NA, not applicable; SIRS, systemic inflammatory response syndrome; VEGF, vascular endothelial growth factor.
**P < 0.001 vs healthy control; *P < 0.05 vs healthy control.; #P < .05 vs SIRS.
TABLE 2 Differences between survivors (n = 35) and
non-survivors (n = 24)
Variable Survivors Non-survivors
APPLEfast score 23 (21-27) 29.5 (24.3-31)**
Neutrophil count (109/L) 10.6 (5.2-20.5) 11.2 (7.6-16.6)
Band neutrophils (%) 1.5 (0.2-7.8) 12.5 (5.5-26.1)**
Urea (mmol/L) 6.4 (4.8-10) 12.3 (8.0-35.2)**
Creatinine (μmol/L) 75.5 (54.5-93.8) 149.5 (69.8-275.3)*
Lactate (mmol/L) 2.0 (1.5-2.8) 3.5 (2.3-5.3)*
Albumin (g/L) 30.2 (24.3-34.3) 23.3 (19.1-25.5)**
Bilirubin (μmol/L) 2.2 (1.3-3.6) 5.0 (2.6-23.3)**
CRP (mg/L) 60 (4.6-116) 112.2 (78.8-171)*
Abbreviations: APPLEfast score, five-parameter acute physiologic and labo-
ratory evaluation score (0–50); CRP, C-reactive protein.
Data are shown as medians and interquartile ranges unless stated
otherwise.
**P < 0.001; *P < 0.05.
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No significant difference between dogs with SIRS and dogs with sepsis
could be detected.
3.3 | Correlation analysis
Plasma Ang-2 concentration was weakly but significantly positively
correlated with VEGF, CRP, the number of band neutrophils, plasma
bilirubin concentration, and alanine aminotransferase (ALT) activity,
and weakly negatively correlated with plasma albumin concentrations
(Table 3, Figure 3). No significant positive correlation was found
between Ang-2 and APPLEfast score (Figure 1C).
Plasma VEGF was moderately positively correlated with the num-
ber of band neutrophils, weakly positively correlated with Ang-2 and
ALT activity, and weakly negatively correlated with plasma albumin
concentration (Table 3). No correlation was found among VEGF, CRP,
lactate, and APPLEfast score (Figure 2C).
3.4 | ROC analysis
To discriminate the healthy from diseased dogs, survivors from non-
survivors, and dogs with SIRS from dogs with sepsis, optimum cutoff
values, sensitivities, specificities, and area under the curve for Ang-2,
FIGURE 1 Plasma Ang-2 concentrations in dogs (A) Comparison of plasma Ang-2 concentrations among healthy control dogs (n = 18), dogs with
SIRS (n = 32), and dogs with sepsis (n = 28). (B) Comparison of plasma Ang-2 concentration between survivors (n = 35) and non-survivors
(n = 24). (C) Lack of a statistically significant correlation between plasma Ang-2 concentrations and APPLEfast score in dogs with SIRS or sepsis.
The central lines in the boxes represent the median values, and the top and bottom of the boxes represent the 75th and 25th percentiles,
respectively. Data points were classified as outliers if they were more than 1.5 times the interquartile range above the third quartile or below the
first quartile. Abbreviations: Ang-2, angiopoietin-2; APPLEfast score: acute patient physiologic and laboratory evaluation score (five-variable
disease severity model based on glucose, albumin, mentation score, platelet count, and lactate); SIRS: systemic inflammatory response syndrome
FIGURE 2 Plasma VEGF concentrations in dogs (A) Comparison of plasma VEGF concentrations among healthy control dogs (n = 7), dogs with
SIRS (n = 32), and dogs with sepsis (n = 28). (B) Comparison of plasma VEGF concentration between survivors (n = 26) and non-survivors
(n = 21). (C) Lack of a statistically significant correlation between plasma VEGF concentrations and APPLEfast score in dogs with SIRS or sepsis.
The central lines in the boxes represent the median values, and the top and bottom of the boxes represent the 75th and 25th percentiles,
respectively. Data points were classified as outliers if they were more than 1.5 times the interquartile range above the third quartile or below the
first quartile. Cut-off for lower limit of detection (LLD) was 15 pg/mL; 27 of 53 samples were below the LLD. Abbreviations: Ang-2, angiopoietin-
2; APPLEfast score, acute patient physiologic and laboratory evaluation score (five-variable disease severity model based on glucose, albumin,
mentation score, platelet count, and lactate); SIRS: systemic inflammatory response syndrome; VEGF, vascular endothelial growth factor
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VEGF, CRP, and APPLEfast score were calculated and are shown in
Table 4. The diagnostic accuracy of plasma Ang-2 concentration to
differentiate between healthy and diseased dogs and between survi-
vors and non-survivors can be considered good. However, Ang-2 did
not have sufficient specificity to differentiate dogs with SIRS from
those with sepsis.
Plasma VEGF concentration had fair accuracy in the differentia-
tion of healthy and diseased dogs. The discriminatory power to differ-
entiate survivors from non-survivors and septic dogs from dogs with
SIRS was poor.
Creactive protein concentration had high diagnostic accuracy to
differentiate between healthy and diseased animals but had very low
sensitivity to differentiate between survivors and non-survivors, and
between dogs with SIRS and those with sepsis.
The optimal cutoff value for the APPLEfast score to discriminate
survivors from non-survivors in this cohort was 29 with a specificity
of 89% and sensitivity of 63%. Specificity and sensitivity for the cutoff
value of 25 for the APPLEfast score were 57% and 75%, respectively.
4 | DISCUSSION
Endothelial activation and dysfunction play a central role in the patho-
genesis of SIRS and sepsis and can lead to the development of distrib-
utive shock, multi-organ dysfunction, and death.36,41 In the context of
systemic inflammation, both VEGF and Ang-2 have been shown to
promote endothelial activation and permeability in human
patients.32,42,43 Sensitive markers to assess endothelial dysfunction
could facilitate an early diagnosis of SIRS or sepsis and allow a better
understanding of the role of the endothelium in critical illness with
the ultimate goal of guiding targeted therapeutic interventions.
The purpose of our study was to assess the diagnostic utility of
Ang-2 and VEGF in dogs with SIRS and sepsis and to evaluate associa-
tions of these 2 markers with disease severity and outcome.
In agreement with results in human patients with SIRS and
sepsis,15,21,24,29 admission plasma Ang-2 concentrations were signifi-
cantly higher in dogs with SIRS or sepsis compared to healthy control
dogs. Admission plasma Ang-2 concentration was significantly higher
in non-survivors than in survivors and had good diagnostic accuracy
to predict negative outcome with an excellent specificity of 87% and
a moderate sensitivity of 50%. Admission Ang-2 was not useful to dif-
ferentiate dogs with sepsis from those with SIRS, which is in agree-
ment with findings of studies in human medicine.44 In human patients,
association of high Ang-2 concentrations with increased mortality in
patients with a range of critical illnesses including SIRS, sepsis, multi-
ple trauma, cancer, and acute and chronic kidney disease has been
shown.10,12,24,30,32,43 Although plasma Ang-2 did not correlate with
the APPLEfast disease severity score in this cohort, most studies in
human medicine report a strong positive relationship between serum
Ang-2 and disease severity scores including Acute Physiology, Age,
and Chronic Health Evaluation II, Sepsis-related Organ Failure Assess-
ment, Simplified Acute Physiology II.15,25,45–47 Given its good overall
performance, plasma Ang-2 concentration may be a promising prog-
nostic biomarker in dogs with SIRS and sepsis. In the human medical
literature, the Ang-2 to Ang-1 ratio sometimes is reported to be of
TABLE 3 Correlation of plasma Ang-2 and VEGF with C-reactive
protein, lactate (n = 77), and APPLEfast score (n = 59)
Variable
Ang-2 VEGF
Spearman ρ P-value Spearman ρ P-value
Angiopoietin-2 (ng/mL) … … 0.35 0.008
VEGF (pg/mL) 0.35 0.008 … …
APPLEfast 0.1 0.55 0.56 0.08
CRP (mg/L) 0.5 <0.001 0.01 0.96
Lactate (mmol/L) 0.16 0.2 0.09 0.56
Bilirubin (μmol/L) 0.35 0.002 0.15 0.28
Albumin (g/L) −0.43 <0.001 −0.47 0.0003
ALT (IU) 0.33 0.003 0.31 0.02
Band neutrophils (%) 0.44 <0.001 0.62 <0.001
Abbreviations: ALT, alanine aminotransferase; APPLEfast score,
five-parameter acute physiologic and laboratory evaluation score (0–50);
CRP, C-reactive protein; VEGF: Vascular endothelial growth factor.
Significance was set at P < 0.05. Significant P-values are printed in bold.
TABLE 4 Sensitivities, specificities, likelihood ratios, and areas under the curve for optimum cutoff concentrations to predict illness (SIRS, sepsis)
and a negative outcome in dogs with SIRS and sepsis
Outcome variable AUC (95% CI) Cutoff Sensitivity (95% CI) Specificity (95% CI) Positive likelihood ratio Negative likelihood ratio
Healthy versus diseased
Ang-2 (ng/mL) 0.83 (0.72-0.9) 13.7 0.61 (0.47-0.73) 1.0 (0.81-1) 61 0.4
VEGF(pg/mL) 0.70 (0.57-0.81) 6.6 0.51 (0.36-0.66) 0.9 (0.59-0.99) 5.1 0.5
CRP (mg/mL) 0.96 (0.88-0.97) 16.7 0.93 (0.84-0.98) 0.95 (0.75-0.99) 18.6 0.1
Survivors versus non-survivors
Ang-2 (ng/mL) 0.75 (0.59–0.85) 25.3 0.5 (0.29–0.71) 0.87 (0.75-0.95) 3.8 0.6
VEGF(pg/mL) 0.68 (0.5-0.8) 59.8 0.38 (0.18-0.62) 0.84 (0.68-0.94) 2.4 0.7
CRP (mg/L) 0.72 (0.6-0.82) 169.7 0.33 (0.16-0.55) 0.93 (0.82-0.98) 4.7 0.7
APPLEfast 0.75 (0.57-0.86) 29 0.63 (0.41-0.81) 0.89 (0.73-0.97) 5.7 0.4
0.75 (0.57–0.86) 25 0.75 (0.53-0.9) 0.57 (0.39-0.74) 1.7 0.4
SIRS versus sepsis
Ang-2 (ng/mL) 0.58 (0.42-0.72) 10.6 0.84 (0.64-0.95) 0.35 (0.2-0.54) 1.3 0.5
VEGF(pg/mL) 0.67 (0.49-0.8) 52.3 0.50 (0.26-0.74) 0.76 (0.56-0.9) 2.1 0.7
CRP (mg/L) 0.54 (0.4-0.7) 143.6 0.44 (0.24-0.65) 0.77 (0.6-0.9) 1.9 0.7
Abbreviations: Ang-2, angiopoietin-2; APPLEfast score, five-parameter acute physiologic and laboratory evaluation score (0–50); AUC, area under the curve;
CI, confidence interval; CRP, C-reactive protein; VEGF, vascular endothelial growth factor.
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even higher prognostic value than Ang-2 alone.48,49 However, there is
currently is no validated assay for measurement of Ang-1 in dogs.
Therefore, the performance of the Ang-2 to Ang-1 ratio for outcome
prediction could not be assessed.
Plasma VEGF concentration was below the level of detection in
all healthy dogs and in the majority of dogs with SIRS. Although some
dogs with sepsis also had very low plasma VEGF concentrations,
median VEGF was higher in this group compared to healthy controls,
but this difference did not reach statistical significance after Bonfer-
roni correction. This result was unexpected but may be linked to dif-
ferences in the pathogenesis between SIRS and sepsis. Microbial
mediators such as bacterial lipopolysaccharide are important triggers
for the production of VEGF and may have more potent effects on
VEGF expression than other nonmicrobial triggers.50
Median VEGF plasma concentrations were not significantly higher
in non-survivors than in survivors, and ROC analysis indicated that its
power to differentiate between survivors and non-survivors was poor.
Plasma VEGF concentration also had low sensitivity and specificity to
differentiate between dogs with SIRS and sepsis and was not corre-
lated with disease severity (APPLEfast score). Plasma VEGF concentra-
tion therefore represents a less useful biomarker than Ang-2 in dogs
with systemic inflammation. These findings align with reports from
human patients where the use of VEGF as an outcome predictor in
patients with systemic inflammation has yielded conflicting results
and its performance was very poor in some studies.35–37 One possible
explanation could be the high biological variability reported for VEGF
in human patients, regardless of the use of standardized methods.51
Similarly, no significant relationship could be identified between blood
VEGF concentrations and a survival prediction index in dogs with SIRS
in a previous study.52
In this cohort, plasma concentrations of Ang-2 and VEGF were
weakly positively correlated with each other. Both also were
significantly positively correlated with band neutrophilia and nega-
tively correlated with plasma albumin concentration which is consid-
ered a negative acute phase protein. These associations support the
current evidence that both VEGF and Ang-2 are induced by inflamma-
tion and act synergistically. Ang-2 counteracts the stabilizing action of
Ang-1 by exposing the endothelium to pro-inflammatory factors such
as VEGF.53 In the presence of VEGF, Ang-2 promotes endothelial acti-
vation and induction of permeability, and in the absence of VEGF, it
destabilizes the existing vessels and leads to vascular regression.54
Furthermore, neutrophil activation by Ang-2 leads to VEGF secretion,
which increases neutrophil adhesion.44
In agreement with previous studies, plasma concentrations of
CRP, a marker of systemic inflammation, were significantly higher in
dogs with SIRS and sepsis compared to healthy controls but did not
discriminate between SIRS and sepsis.55,56 Although Ang-2 was
significantly positively correlated with CRP, no correlation was found
between CRP and VEGF. Because both CRP and VEGF are well-
known pro-inflammatory factors, this lack of correlation was
unexpected. One explanation might be a lower sensitivity of VEGF
compared to CRP as a marker of inflammation. Also, the previously
described biological variability of VEGF could have had an impact.
In this cohort, Ang-2 was a good variable to predict the outcome
using a cutoff plasma concentration of 25.3 ng/mL (sensitivity 50%;
specificity 87%). Therefore, Ang-2 may have utility as a biomarker and
could be used to increase the diagnostic performance of the APPLEfast
score for outcome prediction.
Our study had several limitations: Firstly, because of the relatively
small sample size of 77 dogs, type I or type II errors cannot be
excluded. Secondly, dogs were classified in the SIRS or sepsis group
based on published SIRS criteria.38 Although these criteria have been
widely used by researchers,57 rectal temperature, heart and respira-
tory rate are influenced by pain, stress, and anxiety leading to low
specificity (74%-83%) of these critera.38 Although all cases were care-
fully reviewed for evidence of sepsis, it can be very difficult to defini-
tively prove or rule out an infectious cause of SIRS. In our study, dogs
with gastrointestinal disease including intestinal obstruction (n = 2),
AHDS (n = 2), GDV (n = 1), and ulcerative gastritis (n = 1) without
evidence of gastric or intestinal perforation, were included in the SIRS
group. However, bacterial translocation leading to sepsis cannot
completely be ruled out in these animals. Eight dogs with confirmed
hemangiosarcoma fulfilled the criteria for SIRS and were included in
the study. However, it is well known that Ang-2 production can be
increased in humans with neoplasia.58,59 Our study design does not
allow differentiation of whether Ang-2 was increased in these dogs
because of SIRS or neoplasia, and further studies are underway to
examine Ang-2 dynamics in dogs with neoplasia in more detail. Fur-
thermore, Ang-2 and VEGF only were assessed at admission, which
does not take into account the effect of progression of the underlying
disease and potential complications during treatment. A study investi-
gating the kinetics of serum Ang-2 over several days in patients with
multi-trauma found that Ang-2 on days 4 and 7 after trauma was
increased compared to day 1.31 Similarly, CRP was found in several
studies of dogs to be of greater value in outcome prediction if serial
measurements were performed.60
FIGURE 3 Weak positive correlation between plasma concentrations
of VEGF and Ang-2 in dogs with SIRS and sepsis. Abbreviations: Ang-
2, angiopoietin-2; SIRS: systemic inflammatory response syndrome;
VEGF, vascular endothelial growth factor
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Finally, although an effort was made to exclude dogs that were
euthanized for financial reasons rather than terminal illness, we can-
not fully exclude an effect of euthanasia bias on the outcome analysis
of our study.
In conclusion, Ang-2 is a promising diagnostic and prognostic bio-
marker in dogs with SIRS and sepsis and might be useful to better
understand the pathophysiology of vascular leakage syndromes.
Admission Ang-2 correlated with other known biomarkers (CRP, albu-
min, and bilirubin) that previously have been studied in dogs with SIRS
and sepsis, whereas VEGF did not. Based on our results, plasma VEGF
showed less promise as a useful clinical biomarker compared to Ang-
2, but larger studies in more homogenous populations are needed to
prove this hypothesis.
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